This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Under terms of the deal, Boston Scientific will pay $10 per share to acquire Apollo Endosurgery, well above the company’s previous day’s close of $6 per share.
Dozens of lawmakers banded together to urge the Department of Justice to act on rising anti-transgender threats made against the nation’s children’s hospitals.
The Biden-Harris administration helped expand access to health insurance coverage during the COVID-19 pandemic, but rising costs may still cause some Americans to drop insurance coverage altogether.
In the first few weeks of open enrollment, new signups on the healthcare marketplace, healthcare.gov, are up nearly 40%, according to the Department of Health and Human Services (HHS).
Kaiser Permanente staved off what would have been the largest private-sector nursing strike after reaching an agreement with 21,000 unionized Northern California nurses.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
